Jubilant is a conviction pick. TP ₹1420 (48%)

Jubilant Pharmova is a conviction pick. It is well poised to ride on niche stream of Radiopharma with an established set up. Radiopharma is highly regulated & complex which leads to limited competition, high customer stickiness & low-price erosions. TP ₹1420 (48%)

Jubilant has M-Cap of ₹14800 Cr. Promoters hold 51%. Jhunjhunwala holds 3.28%. Sunil Singhania's Abakkus holds 1.20%. Quant MF holds 1.92%. Radiopharma market is growing at CAGR of 20% & reach $20 Bn by 2030. Allergy Immunotherapy market poised to reach $3 Bn by 2028 at 7% CAGR

https://rakesh-jhunjhunwala.in/jubilant-pharmova-is-a-conviction-pick-buy-for-target-price-of-₹1420-48-upside-icici-direct/